Introduction
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by chronic inflammation within the synovial tissues in multiple joints, and it leads to progressive, erosive destruction of cartilage and joints [
1]. Collagen-induced arthritis (CIA) is a well-established animal model that has been studied extensively because of its similarities to human RA. Although the etiology and pathogenesis of RA have not been completely elucidated, an imbalance between pro- and anti-inflammatory cytokines has been reported to be a key mechanism for joint inflammation and disease progression in CIA as well as in human RA [
2].
Interleukin 10 (IL-10) is an important immunoregulatory cytokine produced by many cell populations, including macrophages, dendritic cells (DCs), T-cell subsets (Th2, Tc2 and Tr1) and B cells [
3]. Lipopolysaccharides (LPSs) induce the expression of IL-10 in macrophages
in vitro and
in vivo[
4‐
6]. Many of the immunosuppressive characteristics of IL-10 can be traced to their effects on macrophages and DCs by preventing the production of the T helper 1 cell (Th1)–associated cytokines IL-2 and interferon γ (IFN-γ). The other profound effects of IL-10 are inhibition of the production of proinflammatory cytokines (IL-1, IL-6 and IL-12), inflammatory chemokines and matrix metalloproteases in macrophages [
7]. IL-10 has been implicated to play a critical immunosuppressive role in autoimmune diseases, including RA [
8‐
11]. In human RA, IL-10 suppresses the expression of tumor necrosis factor α (TNF-α), IL-1β and major histocompatibility complex (MHC) class II in macrophages in the synovial fluid of RA patients [
12]. IL-10 also induces its own expression by human monocyte–derived macrophages. Thus, the anti-inflammatory response mediated by IL-10 provides pivotal regulation of suppression of autoimmune disease development.
Several immune cell types play a role in the pathogenesis of RA, such as fibroblasts, T lymphocytes, B lymphocytes and macrophages [
13]. Macrophages appear to play a critical role in RA development because they are numerous in the inflamed synovial membrane and at the cartilage–pannus junction [
14]. They also possess broad proinflammatory and destructive potential by expressing amounts of the inflammatory cytokines IL-1, TNF-α and IL-6 and by producing matrix metalloproteinases [
15]. Activated macrophages can be broadly classified into classically activated macrophages (M1) and alternatively activated macrophages (M2). Typical stimuli for the M1 macrophages are IFN-γ and LPS, and typical stimuli for the M2 phenotype are IL-4 and IL-13 [
16]. In general, M1 macrophages express high levels of TNF-α, IL-1β, IL-6, IL-12, IL-23 and type I IFN, as well as expressing inducible nitric oxide synthase (iNOS), chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10, CXCL11, C-C chemokine receptor type 7 (CCR7) and human leukocyte antigen, MHC class II molecule, DR isotype. M2 macrophages express high levels of IL-13, IL-1 receptor antagonist (IL-1ra), IL-4 and IL-10, as well as expressing mannose receptor CD206, chitinase 3–like 3, cluster of differentiation 163 (CD163), resistin-like molecule α1, arginase 1 and chitotriosidase [
17‐
19]. Thus, M1 and M2 macrophages promote Th1 and Th2 responses, respectively [
16]. Recently, a key role for macrophages in RA development has been suggested in part by successful treatment of RA by anti-TNF antibodies, because TNF is widely considered to be produced by activated macrophages in inflammatory tissues [
20]. Although the anti-inflammatory effects of IL-10 in CIA have been shown in T cells, but those in macrophages have not yet been studied. Furthermore, the precise IL-10 signaling pathway in macrophages for the inhibition of the pathogenesis of CIA remains to be illuminated.
Recently, IL-17 (also known as IL-17A) is considered the signature cytokine in the Th17 cell population and has been implicated as having a role in the pathogenesis of numerous autoimmune diseases, including RA [
21]. In RA, high levels of IL-17 and its receptor are found in RA synovial fluid and tissues [
21]. IL-17-transgenic mice are prone to develop CIA [
22], whereas inhibition of IL-17 and its receptors with antibodies delay the development of arthritis and reduce its consequences [
23]. Researchers in previous studies have suggested that the IL-23/IL-17 pathway, rather than the IL-12–IFN-γ axis, is essential to promoting the development of CIA [
24]. It has been reported that IL-10 suppresses IL-17 expression by CD11b
+ cells and T cells in
in vitro culture [
25]. However, whether IL-10 regulates IL-17 expression in macrophages from CIA
in vivo has not been studied.
In our present study, we investigated the functions of IL-10 in RA. IL-10-knockout (IL-10−/−) mice and their WT counterparts were used to establish a RA model. The results show that the development of CIA is exacerbated in IL-10−/− mice. Macrophages in IL-10−/− mice significantly upregulate the expression of IL-17 and retinoid-related orphan receptor γt (RORγt) in vivo and in vitro. Moreover, IL-10−/− macrophages might enhance the M1 macrophage–mediated proinflammatory response, which accelerates the RA inflammation response.
Methods
Mice
Male C57BL/6 mice, wild-type (WT) mice and C57BL/6 IL-10−/− mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). The mice were housed under specific pathogen-free conditions. All animal experiments were approved by the Institutional Animal Care and Use Committee of Shenzhen University. We used mice at 10 to 14 weeks of age for experiments.
Collagen-induced arthritis induction
CIA induction was performed according to a previously described protocol with minor modifications [
26,
27]. Briefly, male IL-10
−/− mice and WT mice were immunized intradermally at the base of the tail with 200 μl of chicken type II collagen (CII) (Chondrex, Redmond, WA, USA) emulsified in complete Freund’s adjuvant containing
Mycobacterium tuberculosis (Chondrex). On day 14, these mice were given a second injection of CII dissolved in complete Freund’s adjuvant. Clinical arthritis was evaluated using the following scale: grade 0 = no swelling; grade 1 = slight swelling and erythema; grade 2 = pronounced swelling; and grade 3 = joint rigidity.
Preparation of peritoneal macrophages
The mice were injected intraperitoneally with 2 ml of 5% thioglycollate medium (Sigma-Aldrich, St Louis, MO, USA) for 3 days. They were then killed, and peritoneal macrophages were isolated by lavage with phosphate-buffered saline (PBS). The cells were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (FBS) and antibiotics for 2 hours. Next, the cell cultures were washed to remove nonadherent cells before stimulation, and an aliquot was stained with F4/80 and sorted by flow cytometry.
Preparation of joint macrophages and collection of synovial fluid
Joint macrophages and synovial fluid were collected according to a previously described protocol [
28,
29]. Briefly, after excision of the skin and patellar ligament under a dissecting microscope to expose the synovial membrane, a 30-gauge needle (BD Biosciences, San Jose, CA, USA) was carefully inserted into the membrane, and the synovial cavity was washed by repetitive injections and aspirations with PBS (20 μl) to obtain synovial lavage material. This procedure was repeated five times, and a total volume of 100 μl of synovial lavage fluid was obtained. After that step, joint and paws samples were removed and kept in RPMI 1640 medium (HyClone Laboratories/Thermo Fisher Scientific, Logan, UT, USA) containing 10% FBS (Sijiqing, Zhejiang, China), 100 IU/ml penicillin, 100 μg/ml streptomycin (Beyotime Institute of Biotechnology, Shanghai, China) and 1 mg/ml collagenase (Sigma-Aldrich). The entire mixture was minced and incubated for 1 hour at 37°C in a 5% CO
2 atmosphere. The procedure was repeated three times, and cell suspensions were filtered with a cell strainer after red blood cell lysis. For macrophage isolation, the total of the above-described cell suspensions in a six-well plate for 2 hours and the adherent cells were harvested as joint macrophages. Synovial fluid samples were stored at −80°C prior to performing assays.
Quantitative RT-PCR analysis
RNA samples were extracted by using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and cDNA was prepared by using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA). Quantitative RT-PCR (qRT-PCR) was performed to measure IL-17, RORγt, TNF-α, IL-1β, IL-6, iNOS, IL-13, CD206 and IL-1ra, respectively. The PCR primers used for qRT-PCR were as follows: IL-17, 5′-CAGCAGCGATCATCCCTCAAAG-3′ (forward) and 5′-CAGGACCAGGATCTCTTGCTG-3′ (reverse); for RORγt, 5′-CCGCTGAGAGGGCTTCA-3′ (forward) and 5′-TGCAGGAGTAGGCCACATTACA-3′ (reverse); for TNF-α, 5′-CAAAGGGAGAGTGGTCAGGT-3′ (forward) and 5′-GGCAACAAGGTAGAGAGGC-3′ (reverse); for IL-1β, 5′-CCTTCCAGGATGAGGACATGA-3′ (forward) and 5′-TGAGTCACAGAGGATGGGCTC-3′ (reverse); for IL-6, 5′-ATGGATGCTACCAAACTGGAT-3′ (forward) and 5′-TGAAGGACTCTGGCTTTGTCT-3′ (reverse); for iNOS, 5′-ACATCGACCCGTCCACAGTAT-3′ (forward) and 5′-CAGAGGGGTAGGCTTGTCTC-3′ (reverse); for IL-13, 5′-TGAGCAACATCACACAAGACC-3′ (forward) and 5′-GGCCTTGCGGTTACAGAGG-3′ (reverse); for CD206, 5′-GGCAGGATCTTGGCAACCTAGTA-3′ (forward) and 5′-CCTTTC TTCCGACTCTTCACCC-3′ (reverse); for IL-1ra, 5′-ACAGTAGAAGGAGACAGAAG-3′ (forward) and 5′-GGTGGTAGAGCAGAAGAC-3′ (reverse); and for β-actin, 5′-GTGACGTTGACATCCGTAAAGA-3′ (forward) and 5′-GCCGGACTCATCGTACTCC-3′ (reverse). IL-17, RORγt, TNF-α, IL-1β, IL-6, iNOS, IL-13, CD206 and IL-1ra transcript levels were measured using an
Applied Biosystems 7500 Fast Real-Time PCR
System with SYBR Green PCR Master Mix according to the instructions of the manufacturer (Applied Biosystems, Foster City, CA, USA) and as described previously [
30]. Relative expression levels of target genes were calculated with normalization to β-actin values using the 2
−ΔΔCt comparative cycle threshold method.
Confocal and immunofluorescence microscopy
Peritoneal and joint macrophages were fixed with 4% paraformaldehyde for 10 minutes. After being washed with PBS three times for 5 minutes each, the specimens were permeabilized with 0.1% Triton X-100 in PBS for 5 minutes. Next, they were again washed three times for 5 minutes each with PBS. Nonspecific binding of antibodies was blocked by incubating the coverslips with 3% bovine serum albumin (BSA) for 12 hours. After being washed three times with PBS for 5 minutes each, the cells were then incubated with anti-F4/80 fluorescein isothiocyanate (FITC) antibody at 1:100 (eBioscience, San Diego, CA, USA), Alexa Fluor 647 IL-17 antibody at 1:100 (BD Biosciences) and RORγt phycoerythrin (PE) antibody at 1:100 (BD Biosciences) in 3% BSA at 37°C for 1 hour. After being washed another three times with PBS, nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) at 1:1,000 for 5 minutes. Peritoneal macrophage samples were examined under an Olympus fluorescence microscope (Olympus America, Center Valley, PA, USA). Joint macrophages samples were analyzed under a Leica TCS SP5 confocal laser-scanning fluorescence microscope (Leica Microsystems, Buffalo Grove, IL, USA).
Enzyme-linked immunosorbent assay
Serum and synovial fluid samples were collected from different groups of immunized and nonimmunized mice on day 45 after CII immunization. The levels of IL-17, IFN-γ, IL-6 and IL-1β were measured by enzyme-linked immunosorbent assay (ELISA) using an eBioscience kit. CII-specific immunoglobulin G1 (IgG1) and IgG2a antibodies (eBioscience) were detected by ELISA as previously described [
9].
Western blot analysis
Macrophages and total joint tissue proteins were extracted from CIA mice. For Western blotting, we used the following antibodies: anti-IL-17 (Abcam, Cambridge, MA, USA), anti-RORγt (eBioscience) and anti-β actin (Cell Signaling Technology, Danvers, MA, USA). Immune reaction bands were detected by using horseradish peroxidase–labeled, species-specific secondary antibodies (Cell Signaling Technology) and enhanced chemiluminescence analysis (EMD Millipore, Billerica, MA, USA). Immune reaction bands were scanned using Kodak Image Station 4000MM (Eastman Kodak, Rochester, NY, USA), and images were quantified using Quantity One 1-D Analysis software (Bio-Rad Laboratories).
Flow cytometric analysis
Joint macrophages were prepared and filtered with a cell strainer. F4/80 macrophages were used as pan-macrophage markers, iNOS was used as a marker of M1 macrophages and CD206 was used as a marker of M2 macrophages [
18,
31,
32]. Surface staining was performed using the following monoclonal antibodies: anti-F4/80 FITC (eBioscience), anti-CD206 PE (BioLegend, San Diego, CA, USA). Anti-iNOS allophycocyanin was purchased from BD Biosciences. For intracellular staining of iNOS, Cell Stimulation Cocktail (a cocktail of phorbol 12-myristate 13-acetate, ionomycin, brefeldin A and monensin from eBioscience) was added and cultured for the last 5 hours before flow cytometric analysis as previously described [
25].
Immunofluorescence histochemistry
IL-17+ and F4/80+ macrophages in the knee joints were analyzed by immunofluorescence staining of frozen joint sections from IL-10−/− and WT mice with or without CII immunization. Briefly, knee joint samples were fixed with 4% paraformaldehyde, decalcified with 14% ethylenediaminetetraacetic acid and embedded in optimal cutting temperature compound with 30% sucrose. Macrophages were stained with fluorochrome-conjugated anti-F4/80 FITC antibody (eBioscience) and Alexa Fluor 647 IL-17 antibody (BD Biosciences) in a dark chamber for 30 minutes at room temperature. Nuclei were counterstained with DAPI (1 μg/ml) for 5 minutes. Slides were examined using an Olympus fluorescence microscope.
Histopathological analysis
Paraffin-embedded knee joint tissue sections (5 μm thick) were stained with hematoxylin and eosin. Histopathologic scoring of joint damage was performed under blinded conditions according to a scoring system widely used for evaluating synovitis, cartilage degradation and bone erosion [
33].
Statistical analysis
We used GraphPad version 5.0 software (GraphPad Software, La Jolla, CA, USA) to calculate the mean and SEM values for statistical tests. Comparisons between the WT and IL-10−/− groups were analyzed by performing a two-tailed, unpaired Student’s t-test. P-values <0.05 were considered statistically significant.
Discussion
Previous researchers have clearly demonstrated that inflammatory cytokines are essential for the development of RA [
1,
2] and that taking control of their secretion and action can suppress immune response, delay the development of RA and reduce the consequences of RA. IL-10, an anti-inflammatory cytokine produced by both macrophages and T cells, has been shown to play an important role in the regulation of inflammatory cytokine expression and their function. To assess the functions of IL-10 in CIA, we used C57BL/6 IL-10
−/− mice and WT mice as animal models to induce arthritis. Compared to WT mice, IL-10
−/− mice with CIA were confirmed by histological features to have a higher degree of inflammation in synovial tissues and higher levels of IL-17, IFN-γ, IL-6 and IL-1β in serum (Figure
1). Recent findings revealed that IL-10 signaling in T cells dampened the pathogenesis of CIA by inhibiting the expression of IL-17 [
8,
9]. The function of IL-10 in macrophages in CIA has not yet been studied, however. The results of our present experiments show that IL-10 inhibited the expression of IL-17 and its transcription factor RORγt in F4/80
+ macrophages
in vitro and
in vivo. Similarly, IL-17 and RORγt expression was enhanced in IL-10
−/− mice and IL-10 receptor–deficient (IL-10R
−/−) CD11b
+ macrophages
in vitro[
25]. More importantly, IL-10
−/− mice had a significantly higher number of IL-17-producing F4/80
+ macrophages in the synovium in CIA than WT mice did. Thus, our present findings indicate previously unrecognized IL-10 signaling in F4/80
+ macrophages, which suppresses IL-17 and RORγt expression in F4/80
+ macrophages. Given the substantial IL-17 expression in F4/80
+ macrophages in the synovial tissues in CIA, IL-10 restriction of the IL-17 inflammation response in these cells might alleviate autoimmune inflammation during RA development.
Previously published research results suggest that several cell types, including γδT cells and mast cells [
8,
37], serve as sources of IL-17 in RA. Suurmond
et al. showed that macrophages express IL-17 in RA and osteoarthritis synovium [
37]. The critical effect of macrophages in RA should not be ignored, because the abundance and activation of macrophages in the inflaming synovial membrane/pannus significantly correlate with the severity of RA [
14]. Although CD11b
+ is a marker in murine macrophages, it is also highly expressed on the surface of many leukocytes, including monocytes, neutrophils, natural killer cells and granulocytes [
38]. F4/80, a glycoprotein, has been established as a specific cell surface marker for murine macrophages [
39,
40]. The expression of F4/80 cells in various inflammatory tissues and disease models has been studied extensively [
41]. F4/80 macrophages have been found to express higher levels of the Th1 cytokine IL-12 in inflammatory skin tissues than in healthy skin tissues [
42]. F4/80 macrophages in the intestinal mucosa in Crohn’s disease patients were found to be much higher than in healthy individuals [
43]. Our present results show that F4/80 macrophages had much higher IL-17 expression in the cell cultures stimulated by LPS than in the unstimulated cell cultures. Recently, it has been reported that the expression of IL-17 was significantly increased in CD11b
+ cells of IL-10
−/− and IL-10R
−/− mice compared to WT mice [
25]. However, how IL-10 regulates IL-17 expression in macrophages, especially in specific groups of macrophage (F4/80 macrophages), remains to be clarified. In addition, how this regulation affects the pathogenesis of CIA has not yet been studied. Our results show that the levels of IL-17 in the F4/80 macrophages of the peritoneum and joint tissues in IL-10
−/− mice were significantly higher than those in WT mice (Figures
3C, Figure
4A and
4B), which implies that IL-10 suppresses IL-17 expression in F4/80 macrophages in CIA. Moreover, immunofluorescence microscopy confirmed that the number of IL-17
+ F4/80 macrophages was substantially increased in the synovial tissue of IL-10
−/− mice with CIA (Figure
4D), which suggests that IL-10 might play a role in local regulation of the production of IL-17 in macrophages in CIA. The number of IL-17
+ F4/80 macrophages in synovial tissues increased in tandem with the severity of synovial hyperplasia, cartilage damage and bone erosion. These data imply that the markedly increased number of IL-17
+ F4/80 macrophages in local joint tissue accelerated the pathogenesis of RA.
It is worth noting that IL-17 could induce the production of other proinflammatory cytokines, such as IL-6 and IL-1β, which cooperate to orchestrate inflammation of RA development [
44]. Importantly, in our experiments, IL-10
−/− mice with CIA had significantly higher expression of IL-6 and IL-1β than WT mice with CIA did (data not shown). The results of our experiments indicate that IL-10 deficiency drove IL-17 production in macrophages in CIA joints, we cannot ignore the increased production of IL-17 in other cell types in synovial tissues of IL-10
−/− mice. For instance, it was recently reported that IL-10 signaling in T cells is critical for dampening the pathogenesis of CIA by recruitment of IL-17
+ γδT cells [
8]. Furthermore, the majority of IL-17 expression seems to occur in mast cells of the synovium in RA [
37].
An important question arose from our data: How is the IL-10 signaling pathway involved in the mediation of IL-17 expression in macrophages of the synovium in CIA? RORγt, a specific transcription factor essential for the development of Th17 cells, induces transcription of the genes encoding IL-17 [
45,
46]. Mice with RORγt-deficient T cells are resistant to the induction of autoimmune disease and lack tissue-infiltrating Th17 cells [
46]. Interestingly, recently reported data demonstrate that RORγt expression is enhanced in the spleen cells and thioglycollate-elicited cells of IL-10
−/− mice
in vitro[
25]. However, whether IL-10 is involved in the regulation of RORγt expression in joint F4/80
+ macrophages remains to be studied. In agreement with our hypothesis, the results of our experiments show that IL-10
−/− F4/80
+ macrophages significantly increased the expression of RORγt compared to WT mice F4/80
+ macrophages
in vitro and
in vivo (Figures
3E,
3F,
5A and
5C). These data demonstrate that inhibited IL-17 production by IL-10 in macrophages ois associated with suppression of RORγt expression.
At this stage, we still cannot completely elucidate the mechanisms underlying the upregulation of IL-17 expression in macrophages of CIA IL-10
−/− mice. First, the exact IL-10 signaling cascade involved in the downregulation of IL-17 expression has not yet been fully illuminated. Second, previously published studies have shown that IL-10 exerts its anti-inflammatory effects in macrophages by activating signal transducer and activator of transcription 3 (STAT3) and STAT1 [
7,
47,
48], but the puzzle surrounding relationships between STAT3, STAT1 and RORγt remains to be resolved. Further investigation is necessary to completely understand the mechanism of IL-10 signaling in the mediation of IL-17 expression in macrophages in CIA. Collectively, to the best of our knowledge, we elucidate for the first time that IL-10 attenuation of the development of CIA is associated with suppression of IL-17 and RORγt production in macrophages.
The initiation, development and resolution of RA are determined by a dynamic balance between effector and regulatory immune cell populations. Activated macrophages contribute to RA pathogenesis by secreting proinflammatory cytokines and thereby take part in the Th17/Th1 response [
49,
50]. The polarization of macrophages into the M1 or M2 phenotype depends on the cytokine milieu in the tissue. Macrophages develop into the proinflammatory M1 phenotype in response to IFN-γ and LPS, whereas the anti-inflammatory M2 phenotype is induced by Th2 cytokines, including IL-4 and IL-13. Of note, IL-10, an anti-inflammatory Th2 cytokine, can drive macrophage polarization toward an anti-inflammatory M2 phenotype and can block the differentiation of proinflammatory M1 macrophages [
19,
35]. An important role of the M1 subset of macrophages in exacerbating RA was demonstrated previously [
49,
50]. Our data further confirm that IL-10 deficiency drives macrophage polarization toward the proinflammatory M1 phenotype and increases the expression of M1-mediated proinflammatory cytokines, which contributes to the RA inflammatory response. However, macrophages are plastic cells, because they can switch from an activated M1 state back to M2, and vice versa, under different conditions. Further studies are needed to examine the change of macrophages phenotype in the different stages of RA disease and the molecular mechanism of IL-10-mediated attenuation of CIA by repressing polarization of the proinflammatory M1 phenotype.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LY participated in the conception and design of the study; data acquisition, collection, analysis and interpretation; manuscript writing; critical revision of the manuscript. ZW participated in macrophage isolation, CIA induction experiments, Western blot analysis and critical revision of the manuscript. YL, BC and TY participated in macrophage isolation, RNA and cDNA experiments, RT-PCR analysis and manuscript writing. LLiu participated in immunofluorescence histochemistry, confocal and immunofluorescence microscopy and manuscript writing. JZ, YM and SX participated in flow cytometric analysis, collection of serum and synovial fluid samples and critical revision of the manuscript. LD and LLi participated in ELISA experiments, statistical analysis, manuscript drafting and critical reading of the manuscript. ZH participated in the conception and design of the study, data and statistical analysis, manuscript writing, critical revision of the manuscript and correspondence with the editor of the journal. All authors read and approved the final manuscript.